NASDAQ · Health care

SELLAS Life Sciences Group, Inc. (SLS)

It posted a net loss of $32.5M. At June 30, 2026 it held $138.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.

Price

$11.61

-3.09% on the day · September 25, 2026

52-week range $1.39 to $15.88

Market cap

$2.3B

What SELLAS Life Sciences Group, Inc. does

SELLAS Life Sciences Group, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SLS.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$28.3M	-$26.9M	-$0.25	n/a
2024	n/a	-$31.5M	-$30.9M	-$0.50	n/a
2023	$0	-$37.9M	-$37.3M	-$1.34	n/a
2022	$1M	-$42M	-$41.3M	-$2.13	n/a
2021	$7.6M	-$25.3M	-$20.7M	-$1.34	n/a
2020	$1.9M	-$17M	-$16.8M	-$2.11	n/a

Next report expected around November 11, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 12, 2025. Not a date the company has announced. See the report calendar

Dividends

Fiscal year	Per share	Paid out	Of profit
2019	n/a	$0	n/a
2018	n/a	$487K	n/a
2017	n/a	$0	n/a

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What SELLAS Life Sciences Group, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 11, 2026
Quarterly results 8-K
August 11, 2026
Quarterly report 10-Q · period to June 30, 2026
July 31, 2026
Passive stake (5% or more) SCHEDULE 13G
July 27, 2026
Quarterly results 8-K
June 25, 2026
Executive or director change 8-K
June 18, 2026
Shareholder vote results 8-K
June 16, 2026
Employee stock plan registration S-8
June 2, 2026
Other event 8-K
May 12, 2026
Quarterly results 8-K
May 12, 2026
Quarterly report 10-Q · period to March 31, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 18, 2026. Insider transactions on SEC

Insider trades

What the people running SELLAS Life Sciences Group, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about SLS

What does SELLAS Life Sciences Group, Inc. do?

SELLAS Life Sciences Group, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SLS.

Is SELLAS Life Sciences Group, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $32.5M.

When did SELLAS Life Sciences Group, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026.

Similar companies

Compare SLS with

Compare SLS with any company

Follow SLS

Get an email when SELLAS Life Sciences Group, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow SLS: get an email when it files

Where the numbers come from

Financial figures are the values SELLAS Life Sciences Group, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.